Tadocizumab - Misplaced Pages

Monoclonal antibody Pharmaceutical compound

Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system. It binds to integrin α_IIbβ₃, a fibrinogen and fibronectin receptor found on platelets. The drug is designed for the treatment of patients undergoing percutaneous coronary interventions. It was developed by Yamanōchi Pharma America, Inc.

References

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Tadocizumab, American Medical Association.
Lodish H, Berk A, Matsudaira P, Kaiser CA, Krieger M, Scott MP, Zipursky L, Darnell J (2003). Molecular cell biology (5th ed.). New York: W.H. Freeman. p. 973. ISBN 978-0-7167-4366-8.

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Human	Burosumab Denosumab
Humanized	Blosozumab Romosozumab

Human	Stamulumab

Human	Abelacimab Alirocumab Ascrinvacumab Bentracimab Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Marstacimab Nesvacumab Orticumab Ramucirumab Rinucumab
Mouse	Biciromab Imciromab
Chimeric	Abciximab Volociximab
Humanized	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Concizumab Demcizumab Emicizumab Etaracizumab Faricimab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Human	Anti-amyloid drugs Aducanumab Donanemab Gantenerumab Lecanemab Erenumab Fasinumab Fulranumab Opicinumab
Humanized	Bapineuzumab Crenezumab Eptinezumab Fremanezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Semorinemab Solanezumab Tanezumab

Humanized	Ranibizumab

Human	Bimagrumab Trevogrumab
Humanized	Domagrozumab Landogrozumab

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

This drug article relating to the blood and blood forming organs is a stub. You can help Misplaced Pages by expanding it.